Logo image of 1ILMN.MI

ILLUMINA INC (1ILMN.MI) Stock Fundamental Analysis

BIT:1ILMN - Euronext Milan - US4523271090 - Common Stock - Currency: EUR

81.47  +6.92 (+9.28%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 1ILMN. 1ILMN was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 1ILMN get a neutral evaluation. Nothing too spectacular is happening here. 1ILMN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

1ILMN had positive earnings in the past year.
In the past year 1ILMN had a positive cash flow from operations.
In multiple years 1ILMN reported negative net income over the last 5 years.
In the past 5 years 1ILMN always reported a positive cash flow from operatings.
1ILMN.MI Yearly Net Income VS EBIT VS OCF VS FCF1ILMN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

Looking at the Return On Assets, with a value of -15.61%, 1ILMN is doing worse than 84.21% of the companies in the same industry.
With a Return On Equity value of -40.75%, 1ILMN is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
With an excellent Return On Invested Capital value of 14.46%, 1ILMN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROIC 14.46%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1ILMN.MI Yearly ROA, ROE, ROIC1ILMN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

With an excellent Operating Margin value of 21.07%, 1ILMN belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
1ILMN's Operating Margin has declined in the last couple of years.
1ILMN has a better Gross Margin (66.34%) than 94.74% of its industry peers.
1ILMN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.07%
PM (TTM) N/A
GM 66.34%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
1ILMN.MI Yearly Profit, Operating, Gross Margins1ILMN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

1ILMN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 1ILMN has about the same amount of shares outstanding.
The number of shares outstanding for 1ILMN has been increased compared to 5 years ago.
1ILMN has a worse debt/assets ratio than last year.
1ILMN.MI Yearly Shares Outstanding1ILMN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1ILMN.MI Yearly Total Debt VS Total Assets1ILMN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 3.55 indicates that 1ILMN is not in any danger for bankruptcy at the moment.
1ILMN has a Altman-Z score (3.55) which is in line with its industry peers.
The Debt to FCF ratio of 1ILMN is 2.27, which is a good value as it means it would take 1ILMN, 2.27 years of fcf income to pay off all of its debts.
1ILMN's Debt to FCF ratio of 2.27 is amongst the best of the industry. 1ILMN outperforms 94.74% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that 1ILMN is somewhat dependend on debt financing.
1ILMN has a Debt to Equity ratio (0.63) which is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for 1ILMN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Altman-Z 3.55
ROIC/WACC1.4
WACC10.31%
1ILMN.MI Yearly LT Debt VS Equity VS FCF1ILMN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 1.86 indicates that 1ILMN should not have too much problems paying its short term obligations.
The Current ratio of 1ILMN (1.86) is better than 78.95% of its industry peers.
1ILMN has a Quick Ratio of 1.48. This is a normal value and indicates that 1ILMN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.48, 1ILMN belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.48
1ILMN.MI Yearly Current Assets VS Current Liabilites1ILMN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 278.41% over the past year.
1ILMN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.93% yearly.
1ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -3.47%.
Measured over the past years, 1ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%

3.2 Future

Based on estimates for the next years, 1ILMN will show a very strong growth in Earnings Per Share. The EPS will grow by 21.99% on average per year.
Based on estimates for the next years, 1ILMN will show a small growth in Revenue. The Revenue will grow by 3.86% on average per year.
EPS Next Y76.16%
EPS Next 2Y39.25%
EPS Next 3Y30.79%
EPS Next 5Y21.99%
Revenue Next Year-2.11%
Revenue Next 2Y0.49%
Revenue Next 3Y2.47%
Revenue Next 5Y3.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
1ILMN.MI Yearly Revenue VS Estimates1ILMN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
1ILMN.MI Yearly EPS VS Estimates1ILMN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 28.59, which means the current valuation is very expensive for 1ILMN.
Compared to the rest of the industry, the Price/Earnings ratio of 1ILMN indicates a somewhat cheap valuation: 1ILMN is cheaper than 63.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.48, 1ILMN is valued at the same level.
The Price/Forward Earnings ratio is 20.04, which indicates a rather expensive current valuation of 1ILMN.
Based on the Price/Forward Earnings ratio, 1ILMN is valued a bit cheaper than 68.42% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.04, 1ILMN is valued a bit cheaper.
Industry RankSector Rank
PE 28.59
Fwd PE 20.04
1ILMN.MI Price Earnings VS Forward Price Earnings1ILMN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1ILMN indicates a somewhat cheap valuation: 1ILMN is cheaper than 73.68% of the companies listed in the same industry.
84.21% of the companies in the same industry are more expensive than 1ILMN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.2
EV/EBITDA 12.77
1ILMN.MI Per share data1ILMN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

1ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1ILMN's earnings are expected to grow with 30.79% in the coming years.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y39.25%
EPS Next 3Y30.79%

More info and screens

0

5. Dividend

5.1 Amount

1ILMN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ILLUMINA INC

BIT:1ILMN (6/30/2025, 7:00:00 PM)

81.47

+6.92 (+9.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners107.23%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap12.90B
Analysts74
Price Target94.37 (15.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.22%
Min EPS beat(2)-7.76%
Max EPS beat(2)1.33%
EPS beat(4)2
Avg EPS beat(4)-10.12%
Min EPS beat(4)-60.91%
Max EPS beat(4)26.88%
EPS beat(8)6
Avg EPS beat(8)314.25%
EPS beat(12)9
Avg EPS beat(12)229.49%
EPS beat(16)13
Avg EPS beat(16)180.02%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.95%
Max Revenue beat(2)-0.18%
Revenue beat(4)1
Avg Revenue beat(4)-0.53%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.16%
Revenue beat(16)7
Avg Revenue beat(16)0.05%
PT rev (1m)-8.46%
PT rev (3m)-22.26%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)-8.65%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)-6.1%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)-1.47%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-2.73%
Valuation
Industry RankSector Rank
PE 28.59
Fwd PE 20.04
P/S 3.47
P/FCF 17.2
P/OCF 15.07
P/B 6.36
P/tB 15.42
EV/EBITDA 12.77
EPS(TTM)2.85
EY3.5%
EPS(NY)4.07
Fwd EY4.99%
FCF(TTM)4.74
FCFY5.81%
OCF(TTM)5.41
OCFY6.64%
SpS23.45
BVpS12.8
TBVpS5.28
PEG (NY)0.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROCE 19.27%
ROIC 14.46%
ROICexc 19.56%
ROICexgc 32.43%
OM 21.07%
PM (TTM) N/A
GM 66.34%
FCFM 20.2%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Debt/EBITDA 1.21
Cap/Depr 39.37%
Cap/Sales 2.86%
Interest Coverage 250
Cash Conversion 81.37%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.48
Altman-Z 3.55
F-Score6
WACC10.31%
ROIC/WACC1.4
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
EPS Next Y76.16%
EPS Next 2Y39.25%
EPS Next 3Y30.79%
EPS Next 5Y21.99%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%
Revenue Next Year-2.11%
Revenue Next 2Y0.49%
Revenue Next 3Y2.47%
Revenue Next 5Y3.86%
EBIT growth 1Y1675.86%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year26.49%
EBIT Next 3Y15.01%
EBIT Next 5Y12.66%
FCF growth 1Y484.21%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y334.78%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%